Immuno-oncology (IO) has transformed cancer care ... led to the discovery of novel multi-specific antibodies that target TCR variable beta (Vβ)-chain variants—powerfully activating the right ...

Which is best suited for immuno-oncology? Cancer research and drug ... Checkpoint inhibitors, CAR-T cells, modified TCR T cells, and vaccines in various forms are now the frontier of oncology ...

Medigene has said it will cut 40% of its workforce and delay the start of clinical trials of its lead asset as it re-jigs its ...

Immunocore has secured a piece of biotech industry history, becoming the first company to get an FDA approval for a cancer therapeutic based on T cell receptor (TCR) technology. The US regulator ...

Planegg/Martinsried, November 26, 2024.Medigene AG (Medigene, FSE: MDG1, Prime Standard), an oncology platform company focused on the research ...

Overall, equivalent specificity, safety, and functionality of UniTope-modified rTCRs, compared with unmodified rTCRs, demonstrates the versatility of the UniTope & TraCR System as a high precision ...

Planegg/Martinsried, November 11, 2024.Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused ...